Assay Detail
ADMET
CHEMBL5043230
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of CYP2C9 (unknown origin)
4
Total Activities
4
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | ADMET |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 4 | 5.78 | 6.40 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL5076817 | — | — | 1 | 6.40 |
| CHEMBL5085931 | — | — | 1 | 5.70 |
| CHEMBL5080861 | — | — | 1 | 5.60 |
| CHEMBL5089327 | — | — | 1 | 5.40 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL5076817 | — | IC50 | = | 400.0 | nM | 6.40 |
| CHEMBL5085931 | — | IC50 | = | 2000.0 | nM | 5.70 |
| CHEMBL5080861 | — | IC50 | = | 2500.0 | nM | 5.60 |
| CHEMBL5089327 | — | IC50 | = | 4000.0 | nM | 5.40 |